Gilead Sciences (NQ:GILD)

As of mid-November 2025, a palpable unease has settled over the technology sector, long the darling of investors and the primary engine of market growth. After a period of unprecedented outperformance,...

Topics Stocks

Tech Sector Tremors: Is the AI Bubble Deflating, and What's Next for the Market?

November 13, 2025

Vir Biotechnology Stock Set For Premarket Surge? Retail Trader Hopes Swell As ‘Phenomenal’ HDV Data Sets Stage For Gilead Showdown ↗

Topics Artificial Intelligence Economy Stocks

November 09, 2025

Via Stocktwits

Gilead’s Experimental One Pill Regimen Proved Non-Inferior To Multi-Pill Regimens In Treating HIV ↗

November 13, 2025

The company now plans to submit the data from the study to regulatory authorities.

Via Stocktwits

Gilead's One-Pill HIV Treatment Shows Promise In Late-Stage Trial ↗

November 13, 2025

Gilead's Phase 3 ARTISTRY-1 trial shows its single-tablet HIV regimen of bictegravir and lenacapavir matches the efficacy and safety of current therapy.

Via Benzinga

Explore the top gainers and losers within the S&P500 index in today's session. ↗

November 13, 2025

Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Thursday.

Via Chartmill

2 Supercharged Dividend Stocks to Buy Now ↗

November 13, 2025

Innovative drugmakers often make for solid dividend stocks. These two companies are great examples.

Via The Motley Fool

Topics ETFs Intellectual Property

This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

November 13, 2025

Via Benzinga

Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial

November 13, 2025

Gilead Sciences, Moderna, Artivion, Tenet Healthcare, and Charles River Laboratories Stocks Trade Up, What You Need To Know

November 11, 2025

A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid...

As November 2025 unfolds, a subtle yet significant shift in market sentiment is becoming increasingly palpable among financial analysts and retail investors alike. What was once an almost universally...

Topics Artificial Intelligence Stocks

Is the AI Rally a Bubble? Impact on Commodity Demand and Defensive Stock Rotation

November 11, 2025

Healthcare Sector Navigates Turbulent Waters: Innovation Surges Amidst Political Headwinds

Topics Artificial Intelligence ETFs Economy

November 10, 2025

New York, NY – November 10, 2025 – The S&P 500 Healthcare sector presented a mixed picture today, with the broader index showing a modest uptick while significant segments, particularly health insurers...

GBK Brand Bar and Meals on Me Host the Official Backstage Lounge at the 40th Annual Rock & Roll Hall of Fame Induction Ceremony Rehearsals

Topics Artificial Intelligence Economy Government

November 10, 2025

November 10, 2025 -- During rehearsals leading up to the Induction Ceremony, GBK welcomed some of the world's biggest musicians from legendary icons to today's top superstars.

Via 24-7 Press Release

What's going on in today's session: S&P500 movers ↗

November 07, 2025

Curious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session.

Via Chartmill

Gilead's Trodelvy Misses Main Goal In Breast Cancer Study But Shows Early Survival Trend ↗

November 07, 2025

Gilead's Trodelvy missed a key goal in breast cancer, while Livdelzi showed durable efficacy and safety in long-term liver disease studies.

Via Benzinga

Gilead Provides Update on Phase 3 ASCENT-07 Study

November 07, 2025

Gilead’s Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression

November 07, 2025

The third-quarter 2025 earnings season, largely drawing to a close in early November, has proven to be a dynamic and often surprising period for investors. While a significant majority of S&P 500...

Navigating the Volatility: Q3 2025 Earnings Season Delivers Both Cheers and Concerns

November 06, 2025

San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025....

Topics Artificial Intelligence Economy Stocks

Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High

November 06, 2025

Gilead Sciences’ third quarter was marked by strong sales growth in its HIV and liver disease portfolios, but the market responded negatively due to ongoing concerns about oncology revenue and broader...

Topics Intellectual Property

Gilead Sciences’s Q3 Earnings Call: Our Top 5 Analyst Questions

November 06, 2025

Gilead Sciences (GILD) appears undervalued with a low P/E ratio, strong profitability, no debt, and a solid dividend, fitting classic value investing principles.

Topics Earnings

3 Cash-Rich Stocks With High Growth Potential Right Now ↗

November 05, 2025

Via MarketBeat

10 Health Care Stocks Whale Activity In Today's Session ↗

November 05, 2025

Via Benzinga

Gilead Sciences Inc (NASDAQ:GILD) Appears as a Decent Value Stock ↗

November 05, 2025

Via Chartmill

Moderna Earnings: What To Look For From MRNA

November 04, 2025

Biotechnology company Moderna (NASDAQ:MRNA) will be reporting results this Thursday before the bell. Here’s what investors should know.

AI Unleashes a New Era in Cell and Gene Therapy: A Quarter Century Update Reveals Transformative Potential

November 04, 2025

The burgeoning fields of cell and gene therapy (CGT) are on the cusp of a profound revolution, driven by the relentless advancements in artificial intelligence. This transformative impact was a central...

Via TokenRing AI

Topics Artificial Intelligence

Gilead Sciences to Present at Upcoming Investor Conferences

November 04, 2025

Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025

November 03, 2025

Gilead Sciences Inc (NASDAQ:GILD): A Dividend Stock with a Secure Payout and Strong Fundamentals ↗

November 03, 2025

Gilead Sciences (GILD) offers a 2.64% dividend yield with a very low payout ratio, strong profitability, and a debt-free balance sheet, making it a compelling dividend stock.

Via Chartmill

Amgen Earnings: What To Look For From AMGN

November 02, 2025

Biotech company Amgen (NASDAQ:AMGN) will be reporting earnings this Tuesday after market close. Here’s what to look for.

Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results this Monday after the bell. Here’s what to expect.

Topics Artificial Intelligence

What To Expect From Myriad Genetics’s (MYGN) Q3 Earnings

November 01, 2025